logo
Plus   Neg
Share
Email

Gilead To Present New Data From Its HIV Research & Development Program - Quick Facts

Gilead Sciences, Inc. (GILD) announced that new data from the company's HIV research and development program will be presented at the 23rd International AIDS Conference. Phase 1 trial results supporting further evaluation of a six-month dosing interval for a sustained delivery formulation of Gilead's investigational HIV-1 capsid inhibitor, lenacapavir (GS-6207), will be presented at the Conference.

The company said the HIV treatment data to be presented includes a pooled analysis of four international trials evaluating the safety and efficacy of Biktarvy in adults aged 65 or older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
Follow RTT